Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 3Q:25 results, confirming the pre-new drug application (NDA) meeting with the FDA in 4Q:25 to see if an NDA can be accepted using existing ...

VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and ...

Diality Inc. today announced that three posters highlighting new data from the first clinical use of the Moda-flx™ Hemodialysis System will be presented during the American Society of Nephrology’s ...

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced ...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...

A presentation about the many different types of fraud that can impact college students was given in Lumpkin Hall on Oct 21. Jason Donnelly, the vice president and treasury management relationship ...

Professional-grade presentations on advanced statistics, MCMC methods, and data science applications. Created by ESMAD faculty and Mysense.ai Lead Data Scientist. Includes theoretical foundations, ...

Company will provide an overview of the pritelivir clinical development program in two oral presentations including a comprehensive Phase 2 data overview Updated safety and pharmacokinetic results of ...

Organizations and scholars concerned with academic freedom are raising the alarm over the firing of a Texas A&M University instructor who was dismissed on Tuesday after videos of a classroom exchange ...

Congress can't even debate a bill without wasting money. In the first two months of this year, it spent at least $27,500 "on printing charts, props, and posters, sticking them on easels (or making ...

Structure Therapeutics to present promising data on ACCG-2671 for obesity and GLP-1 receptor agonists for Parkinson's at ADA 2025. Structure Therapeutics announced two late-breaking poster ...